FDA Investigates Confirmed Insertional Oncogenesis With Spinal Muscular Atrophy Gene Therapy

10 Nov 2026 0 comments

Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.

Source: NeurologyLive Published 09 Nov 2026 Imported 09 Nov 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment